119,230 Shares of Thermo Fisher Scientific Inc. $TMO Purchased by Mirae Asset Global Investments Co. Ltd.

Posted by Francis Steltz on Nov 1st, 2026

Mirae Asset Global Investments Co. Ltd. purchased a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO – Free Report) in the 3rd quarter, HoldingsChannel.com reports. The fund purchased 119,230 shares of the medical research company’s stock, valued at approximately $80,486,000.

A number of other hedge funds also recently modified their holdings of TMO. BlackRock Inc. bought a new stake in shares of Thermo Fisher Scientific during the second quarter valued at approximately $15,501,867,000. Corient Private Wealth LP acquired a new position in shares of Thermo Fisher Scientific in the second quarter valued at $382,547,000. Bank of New York Mellon Corp bought a new position in Thermo Fisher Scientific in the second quarter worth $1,974,561,000. Bank of America Corp DE bought a new position in Thermo Fisher Scientific in the second quarter worth $1,952,930,000. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in Thermo Fisher Scientific by 0.9% during the second quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 2,472,524 shares of the medical research company’s stock worth $1,239,625,000 after buying an additional 22,827 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of TMO stock opened at $696.78 on Friday. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $711.85. The stock has a 50-day moving average price of $654.87 and a 200 day moving average price of $552.94. The company has a quick ratio of 1.41, a current ratio of 1.81 and a debt-to-equity ratio of 0.71. The firm has a market cap of $257.63 billion, a price-to-earnings ratio of 36.75, a PEG ratio of 2.84 and a beta of 0.87.

Thermo Fisher Scientific (NYSE:TMO – Get Free Report) last posted its quarterly earnings results on Wednesday, October 21st. The medical research company reported $6.68 earnings per share for the quarter, topping analysts’ consensus estimates of $6.40 by $0.28. Thermo Fisher Scientific had a net margin of 14.94% and a return on equity of 17.33%. The business had revenue of $12.14 billion during the quarter, compared to the consensus estimate of $11.95 billion. During the same period in the previous year, the firm posted $5.79 earnings per share. Thermo Fisher Scientific’s revenue for the quarter was up 9.1% compared to the same quarter last year. Research analysts expect that Thermo Fisher Scientific Inc. will post 25.26 EPS for the current year.

Insider Buying and Selling at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Michael Shafer sold 25,500 shares of the company’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the sale, the executive vice president owned 20,994 shares in the company, valued at approximately $12,596,400. The trade was a 54.85% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Marc Casper sold 275 shares of the stock in a transaction on Monday, August 24th. The shares were sold at an average price of $627.05, for a total value of $172,438.75. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares in the company, valued at approximately $77,707,171.25. This trade represents a 0.22% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 76,199 shares of company stock worth $45,896,780 over the last quarter. 0.33% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Jefferies Financial Group restated a “buy” rating and issued a $630.00 price objective on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. Robert W. Baird lifted their target price on shares of Thermo Fisher Scientific from $723.00 to $756.00 and gave the company an “outperform” rating in a research report on Thursday, October 22nd. Stifel Nicolaus upped their target price on shares of Thermo Fisher Scientific from $650.00 to $775.00 and gave the company a “buy” rating in a research note on Thursday, October 22nd. Royal Bank Of Canada increased their price target on shares of Thermo Fisher Scientific from $580.00 to $730.00 and gave the stock a “sector perform” rating in a research report on Thursday, October 22nd. Finally, Argus increased their price target on shares of Thermo Fisher Scientific from $560.00 to $780.00 and gave the stock a “buy” rating in a research report on Friday. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating, four have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $689.10.

Read Our Latest Research Report on Thermo Fisher Scientific

Thermo Fisher Scientific Profile

(Free Report)

Thermo Fisher Scientific Inc is a global supplier of laboratory products, analytical instruments, reagents, consumables, software and services used in scientific research, healthcare, pharmaceuticals, biotechnology and industrial applications. The company serves customers ranging from academic institutions and government agencies to hospitals, clinical laboratories and pharmaceutical manufacturers.

Its offerings include instruments and systems for genetic analysis, mass spectrometry, chromatography, electron microscopy and materials science, as well as molecular biology reagents, cell culture products, laboratory plastics and research chemicals.